| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 12.0 | 16.0 | 25.6 |
| Other income | 5.7 | 0.0 | 4.2 |
| Total income | 17.7 | 16.0 | 29.8 |
| Profit before exceptional items & tax | -147.0 | -16.6 | -5.5 |
| Profit before tax | -147.0 | -16.6 | -5.5 |
| Net profit | -147.1 | -16.6 | -5.6 |
| Operating margin | -830.5% | -103.8% | -18.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -53.10% |
|---|
BSE results filing, NSE: VIVIMEDLAB. Figures extracted from the filing.
Vivimed Labs Ltd: key numbers
- Share price
- ₹5.55
- Market cap
- ₹46.02 Cr
- Revenue (annual)
- ₹69.99 Cr
- Net profit (annual)
- ₹-176.5 Cr
- P/E (TTM)
- -0.3×Sector 50.4×
- Promoter holding
- 7.57%-0.20% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Vivimed Labs Ltd
All →Vivimed Labs Insolvency Petition
Vivimed Labs Limited, currently under CIRP, has scheduled the 8th meeting of the Committee of Creditors for September 29, 2026, via audio-visual means.
Vivimed Labs Other Announcement
Vivimed Labs is seeking a three-month extension from the Registrar of Companies to convene its Annual General Meeting for the financial year 2025-26.
Vivimed Labs Other Announcement
Vivimed Labs Limited, currently under corporate insolvency resolution, has announced its 7th Committee of Creditors meeting scheduled for September 10, 2026, to be held virtually.